Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Juba, South Sudan: a population-based study.

Autor:	Wiens KE; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Mawien PN; Republic of South Sudan Ministry of Health, Juba, South Sudan., Rumunu J; Republic of South Sudan Ministry of Health, Juba, South Sudan., Slater D; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA., Jones FK; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Moheed S; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA., Caflish A; Displacement Tracking Matrix, International Organization for Migration, Juba, South Sudan., Bior BK; Republic of South Sudan Ministry of Health, Juba, South Sudan., Jacob IA; Republic of South Sudan Ministry of Health, Juba, South Sudan., Lako RLL; Republic of South Sudan Ministry of Health, Juba, South Sudan., Guyo AG; World Health Organization, Juba, South Sudan., Olu OO; World Health Organization, Juba, South Sudan., Maleghemi S; World Health Organization, Juba, South Sudan., Baguma A; World Health Organization, Juba, South Sudan.; Kabale University School of Medicine, Department of Microbiology and Immunology., Hassen JJ; World Health Organization, Juba, South Sudan., Baya SK; World Health Organization, Juba, South Sudan., Deng L; Republic of South Sudan Ministry of Health, Juba, South Sudan., Lessler J; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Demby MN; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Sanchez V; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA., Mills R; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA., Fraser C; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA., Charles RC; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Harris JB; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.; Department of Pediatrics, Harvard Medical School, Boston, MA, USA., Azman AS; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.; Médecins Sans Frontières, Geneva, Switzerland.; Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland., Wamala JF; World Health Organization, Juba, South Sudan.
Jazyk:	angličtina
Zdroj:	MedRxiv : the preprint server for health sciences [medRxiv] 2021 Mar 12. Date of Electronic Publication: 2021 Mar 12.
DOI:	10.1101/2021.03.08.21253009
Abstrakt:	Background: Relatively few COVID-19 cases and deaths have been reported through much of sub-Saharan Africa, including South Sudan, although the extent of SARS-CoV-2 spread remains unclear due to weak surveillance systems and few population-representative serosurveys. Methods: We conducted a representative household-based cross-sectional serosurvey in Juba, South Sudan. We quantified IgG antibody responses to SARS-CoV-2 spike protein receptor-binding domain and estimated seroprevalence using a Bayesian regression model accounting for test performance. Results: We recruited 2,214 participants from August 10 to September 11, 2020 and 22.3% had anti-SARS-CoV-2 IgG titers above levels in pre-pandemic samples. After accounting for waning antibody levels, age, and sex, we estimated that 38.5% (32.1 - 46.8) of the population had been infected with SARS-CoV-2. For each RT-PCR confirmed COVID-19 case, 104 (87-126) infections were unreported. Background antibody reactivity was higher in pre-pandemic samples from Juba compared to Boston, where the serological test was validated. The estimated proportion of the population infected ranged from 30.1% to 60.6% depending on assumptions about test performance and prevalence of clinically severe infections. Conclusions: SARS-CoV-2 has spread extensively within Juba. Validation of serological tests in sub-Saharan African populations is critical to improve our ability to use serosurveillance to understand and mitigate transmission.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu